Success Metrics

Active Trials
2(67%)

Phase Distribution

Ph phase_3
1
33%
Ph phase_2
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 3Large-scale testing
1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Recruiting2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 21 (50.0%)
Phase 31 (50.0%)

Trials by Status

not_yet_recruiting133%
recruiting267%

Recent Activity

2 active trials
Showing 3 of 3
recruitingphase_3

Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

NCT07195591
not_yet_recruitingphase_2

Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile®

NCT07821112
recruiting

Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)

NCT04427384

Clinical Trials (3)

Showing 3 of 3 trials
NCT07195591Phase 3

Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

Recruiting
NCT07821112Phase 2

Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile®

Not Yet Recruiting
NCT04427384

Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
3